Additionally, NO has been shown to reduce EGFR signaling and act synergistically with gefitinib, an EGFR tyrosine kinase inhibitor, in prostate and lung cancers, while altered s-nitrosation in HER2+ breast cancer is linked to trastuzumab resistance. Here, ERBB2 is linked to lung carcinoma.